Bioelectronics Corp (BIEL)

[3331]

Vertex just submitted VX-548/Suzetrigine for FDA approval. It's considered to be a huge breakthrough as an opioid alternative, and VRTX stock has increased accordingly. However, while it is effective, it's not as effective as opioids, but is non-addictive with minimal side effects. Based on the data Dr. Ilfeld has released so far, it seems Actipatch could have similar results as Suzetrgine, but has the advantage of being drug-free and more cost effective. Have to wait for Dr. Ilfeld's conclusions.